Cargando…
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study
AIMS: To determine the association between metformin use and mortality and ARDS incidence in patients with COVID-19 and type 2 diabetes. METHODS: This study was a multi-center retrospective analysis of COVID-19 patients with type 2 diabetes and admitted to four hospitals in Hubei province, China fro...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833191/ https://www.ncbi.nlm.nih.gov/pubmed/33310173 http://dx.doi.org/10.1016/j.diabres.2020.108619 |
_version_ | 1783642009436684288 |
---|---|
author | Jiang, Nan Chen, Zhenyuan Liu, Li Yin, Xiaoxv Yang, Heping Tan, Xiangping Wang, Jing Li, Hui Tian, Mengge Lu, Zuxun Xiong, Nian Gong, Yanhong |
author_facet | Jiang, Nan Chen, Zhenyuan Liu, Li Yin, Xiaoxv Yang, Heping Tan, Xiangping Wang, Jing Li, Hui Tian, Mengge Lu, Zuxun Xiong, Nian Gong, Yanhong |
author_sort | Jiang, Nan |
collection | PubMed |
description | AIMS: To determine the association between metformin use and mortality and ARDS incidence in patients with COVID-19 and type 2 diabetes. METHODS: This study was a multi-center retrospective analysis of COVID-19 patients with type 2 diabetes and admitted to four hospitals in Hubei province, China from December 31st, 2019 to March 31st, 2020. Patients were divided into two groups according to their exposure to metformin during hospitalization. The outcomes of interest were 30-day all-cause mortality and incidence of ARDS. We used mixed-effect Cox model and random effect logistic regression to evaluate the associations of metformin use with outcomes, adjusted for baseline characteristics. RESULTS: Of 328 patients with COVID-19 and type 2 diabetes included in the study cohort, 30.5% (100/328) were in the metformin group. In the mixed-effected model, metformin use was associated with the lower incidence of ARDS. There was no significant association between metformin use and 30-day all-cause mortality. Propensity score-matched analysis confirmed the results. In the subgroup analysis, metformin use was associated with the lower incidence of ARDS in females. CONCLUSIONS: Metformin may have potential benefits in reducing the incidence of ARDS in patients with COVID-19 and type 2 diabetes. However, this benefit differs significantly by gender. |
format | Online Article Text |
id | pubmed-7833191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78331912021-01-26 Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study Jiang, Nan Chen, Zhenyuan Liu, Li Yin, Xiaoxv Yang, Heping Tan, Xiangping Wang, Jing Li, Hui Tian, Mengge Lu, Zuxun Xiong, Nian Gong, Yanhong Diabetes Res Clin Pract Article AIMS: To determine the association between metformin use and mortality and ARDS incidence in patients with COVID-19 and type 2 diabetes. METHODS: This study was a multi-center retrospective analysis of COVID-19 patients with type 2 diabetes and admitted to four hospitals in Hubei province, China from December 31st, 2019 to March 31st, 2020. Patients were divided into two groups according to their exposure to metformin during hospitalization. The outcomes of interest were 30-day all-cause mortality and incidence of ARDS. We used mixed-effect Cox model and random effect logistic regression to evaluate the associations of metformin use with outcomes, adjusted for baseline characteristics. RESULTS: Of 328 patients with COVID-19 and type 2 diabetes included in the study cohort, 30.5% (100/328) were in the metformin group. In the mixed-effected model, metformin use was associated with the lower incidence of ARDS. There was no significant association between metformin use and 30-day all-cause mortality. Propensity score-matched analysis confirmed the results. In the subgroup analysis, metformin use was associated with the lower incidence of ARDS in females. CONCLUSIONS: Metformin may have potential benefits in reducing the incidence of ARDS in patients with COVID-19 and type 2 diabetes. However, this benefit differs significantly by gender. Elsevier B.V. 2021-03 2020-12-10 /pmc/articles/PMC7833191/ /pubmed/33310173 http://dx.doi.org/10.1016/j.diabres.2020.108619 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Jiang, Nan Chen, Zhenyuan Liu, Li Yin, Xiaoxv Yang, Heping Tan, Xiangping Wang, Jing Li, Hui Tian, Mengge Lu, Zuxun Xiong, Nian Gong, Yanhong Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
title | Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
title_full | Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
title_fullStr | Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
title_full_unstemmed | Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
title_short | Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
title_sort | association of metformin with mortality or ards in patients with covid-19 and type 2 diabetes: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833191/ https://www.ncbi.nlm.nih.gov/pubmed/33310173 http://dx.doi.org/10.1016/j.diabres.2020.108619 |
work_keys_str_mv | AT jiangnan associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT chenzhenyuan associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT liuli associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT yinxiaoxv associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT yangheping associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT tanxiangping associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT wangjing associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT lihui associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT tianmengge associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT luzuxun associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT xiongnian associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy AT gongyanhong associationofmetforminwithmortalityorardsinpatientswithcovid19andtype2diabetesaretrospectivecohortstudy |